Table 4. Test Results in Patients Achieving SVR versus Nonresponders.
| SVR N |
SVR QLFT at Baseline X±SD | Δ QLFT in SVR M24-Base | P value For Δ QLFT in SVR | NR N |
NR QLFT at Baseline X±SD | Δ QLFT in NR M24-Base | P value For Δ QLFT in NR | P value ΔQLFT SVR vs NR | |
|---|---|---|---|---|---|---|---|---|---|
| Standard Laboratory Tests | |||||||||
| Bilirubin (mg/dL) | 24 | 0.74 ±0.37 | 0.07 ±0.27 | 0.21 | 68 | 0.73 plusmn;0.32 | 0.35 ±0.54 | <0.0001 | 0.002 |
| Albumin (g/dL) | 24 | 3.90 ±0.35 | 0.03 ±0.37 | 0.70 | 68 | 3.67 ±0.36 | −0.12± 0.40 | 0.02 | 0.11 |
| INR | 24 | 1.01 ±0.09 | 0.05 ±0.09 | 0.01a | 68 | 1.04 ±0.12 | 0.07 ±0.09 | <0.0001 | 0.43 |
| Platelets (10−3/μL) | 24 | 177 ±59 | 22 ±40 | 0.01 | 68 | 160 ±71 | −13 ±33 | 0.003 | 0.0001 |
| Tests of Metabolism | |||||||||
| Caffeine kelim (h−1) | 22 | 0.08 ±0.04 | 0.03 ±0.05 | 0.02 | 59 | 0.05 ±0.04 | 0 ±0.03 | 0.57 | 0.01 |
| Antipyrine kelim (h−1) | 17 | 0.04 ±0.02 | 0.01 ±0.02 | 0.05 | 40 | 0.03 ±0.01 | 0 ±0.01 | 0.87 | 0.05 |
| Antipyrine Cl (ml/min) | 17 | 39.6 ±13.6 | 12.1 ±19.6 | 0.02 | 39 | 28.9 ±13.7 | −0.6 ±8.2 | 0.63 | 0.02 |
| MEGX15min (ng/ml) | 24 | 19.4 ±12.9 | 5.9 ±18.7 | 0.14 | 64 | 16.2 ±11.7 | −0.6 plusmn;13.4 | 0.71 | 0.13 |
| MEGX30min (ng/ml) | 24 | 23.0 ±8.8 | 2.1 ±14.1 | 0.48 | 63 | 20.8 ±11.8 | 0.1 ±14.0 | 0.97 | 0.55 |
| Tests of Total Hepatic Blood Flow | |||||||||
| Cholate kelim (min−1) | 24 | 0.09 ±0.02 | 0.01 ±0.03 | 0.25 | 67 | 0.09 +0.03 | −0.01 ±0.03 | 0.03 | 0.04 |
| Cholate Cliv (ml/min) | 24 | 427 ±115 | −33 ±107 | 0.14 | 67 | 394 +125 | −60 ±121 | 0.0001 | 0.33 |
| GEC (mg/kg·min) | 23 | 4.88 ±1.10 | 0.05 ±0.84 | 0.80 | 66 | 4.75 +1.22 | −0.16 ±0.88 | 0.15 | 0.34 |
| Tests of Portal Circulation | |||||||||
| Cholate Cloral (ml/min) | 24 | 1371 ±329 | 437 ±494 | 0.0002 | 67 | 1107 ±551 | −102 ±377 | 0.03 | <0.0001 |
| Cholate Shunt (%) | 24 | 32 ±8 | −8 ±10 | 0.0003 | 67 | 41 ±15 | 0 ±16 | 0.85 | 0.003 |
| Tests of Hepatic Parenchyma | |||||||||
| Perfused Hepatic Mass | 20 | 102.3 ±4.1 | 1.6 ±3.1 | 0.03 | 65 | 96.3 ±9.0 | −2.7 ±15.6 | 0.17 | 0.04 |
| Liver Volume (ml) | 20 | 1635 ±358 | −42 ±178 | 0.30 | 65 | 1691 ±361 | −55 ±318 | 0.17 | 0.82 |
a
Although the change in INR was significant, the change was in the direction of worsening with SVR.
P values that are in bold typeface indicate significant change in the test from baseline or in the comparison of changes between patients achieving SVR and nonresponders. The gray shading identifies tests that improved significantly with SVR and were significant in the comparison of changes in the test between SVR and NR.
Abbreviations: Cl, clearance; oral, orally administered; iv, intravenously administered; k, rate constant of elimination; MEGX, monoethylglycine xylidide; GEC, galactose elimination capacity.